Skip to content
Axcess News – Lifestyle
Author:
Faron Pharmaceuticals
Faron Pharmaceuticals Ltd’s Annual Report 2025 Published
March 7, 2026
Faron’s Financial Statements Release 1 January to 31 December 2025
March 7, 2026
Faron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting
March 6, 2026
Faron and City of Hope in Process of Developing a Phase II Investigator-Initiated Trial of Bexmarilimab in Relapsed/Refractory MDS
March 6, 2026
Faron’s Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 2026
March 5, 2026
Faron Announces Phase II BEAM-X IIT Led by the Nordic AML Group Evaluating Bexmarilimab in Post-Transplant AML
March 5, 2026
←
Previous Page
1
2
3
4